Skip to Content

How does Asparlas (calaspargase pegol-mknl) compare to Oncaspar (pegaspargase)?

Medically reviewed by J. Stewart, BPharm. Last updated on Mar 29, 2019.

Official Answer

by Drugs.com

Asparlas is given no more frequently than every 21 days and Oncaspar is given no more frequently than every 14 days. Oncaspar is can be given intramuscularly or intravenously while Asparlas is only given intravenously.

Asparlas (calaspargase pegol-mknl) and Oncaspar (pegaspargase) are both forms of PEGylated asparaginase indicated for use in the treatment of acute lymphoblastic leukemia (ALL).

Asparlas provides for a longer interval between doses compared to Oncaspar, and has as an extended shelf life.

Asparlas (calaspargase pegol-mknl) Injection
FDA Approved: 2018
Dosage Interval: Asparlas is administered intravenously no more frequently than every 21 days.
Storage: Store in refrigerator at 2°C to 8°C (36°F to 46°F).
Unopened vials may be stored at room temperature (15°C to 25°C [59°F to 77°F]) for no more than 48 hours.

Oncaspar (pegaspargase) Injection
FDA Approved: 1994
Dosage Interval: Oncaspar is administered intramuscularly or intravenously no more frequently than every 14 days.
Storage: Store in refrigerator at 2ºC to 8ºC (36°F to 46°F).

Related Drug Information

Hide